158 related articles for article (PubMed ID: 18444839)
21. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
Nüesch R; Ananworanich J; Srasuebkul P; Chetchotisakd P; Prasithsirikul W; Klinbuayam W; Mahanontharit A; Jupimai T; Ruxrungtham K; Hirschel B
AIDS; 2008 Jan; 22(1):152-4. PubMed ID: 18090405
[TBL] [Abstract][Full Text] [Related]
22. Once-daily dosing of nevirapine in HAART.
Clotet B
J Antimicrob Chemother; 2008 Jan; 61(1):13-6. PubMed ID: 18006524
[TBL] [Abstract][Full Text] [Related]
23. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients.
Ratcliffe L; Beadsworth MB; Pennell A; Phillips M; Vilar FJ
AIDS; 2011 May; 25(8):1051-6. PubMed ID: 21346511
[TBL] [Abstract][Full Text] [Related]
24. Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.
Fabbiani M; Bracciale L; Doino M; D'Avino A; Marzocchetti A; Navarra P; Cauda R; De Luca A; Di Giambenedetto S
J Infect; 2011 Apr; 62(4):319-21. PubMed ID: 21329725
[No Abstract] [Full Text] [Related]
25. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
Stellbrink HJ; Orkin C; Arribas JR; Compston J; Gerstoft J; Van Wijngaerden E; Lazzarin A; Rizzardini G; Sprenger HG; Lambert J; Sture G; Leather D; Hughes S; Zucchi P; Pearce H;
Clin Infect Dis; 2010 Oct; 51(8):963-72. PubMed ID: 20828304
[TBL] [Abstract][Full Text] [Related]
26. [Experience with nevirapine taken once daily in 93 HIV-infected patients].
Allavena C; François C; Reliquet V; Perre P; Michau C; Peytavin G; Raffi F
Pathol Biol (Paris); 1999 May; 47(5):563-5. PubMed ID: 10418041
[TBL] [Abstract][Full Text] [Related]
27. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.
Pinnetti C; Baroncelli S; Villani P; Fantoni M; Tozzi V; De Luca A; Cauda R; Anzidei G; Cusato M; Regazzi M; Floridia M; Tamburrini E
J Antimicrob Chemother; 2010 Sep; 65(9):2050-2. PubMed ID: 20630894
[No Abstract] [Full Text] [Related]
28. Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial).
Weberschock T; Gholam P; Hueter E; Flux K; ; Hartmann M
Eur J Med Res; 2009; 14(12):516-9. PubMed ID: 20149984
[TBL] [Abstract][Full Text] [Related]
29. The risk of HIV drug resistance following implementation of pre-exposure prophylaxis.
van de Vijver DA; Boucher CA
Curr Opin Infect Dis; 2010 Dec; 23(6):621-7. PubMed ID: 20847692
[TBL] [Abstract][Full Text] [Related]
30. Initial results reported on raltegravir once-daily dosing.
AIDS Patient Care STDS; 2011 Feb; 25(2):123. PubMed ID: 21370546
[No Abstract] [Full Text] [Related]
31. Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era.
De Clercq E
Biochem Pharmacol; 2012 Aug; 84(3):241-8. PubMed ID: 22504027
[TBL] [Abstract][Full Text] [Related]
32. Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
Allavena C; Dailly E; Reliquet V; Bonnet B; Pineau S; André-Garnier E; Boutoille D; Bouquié R; Raveleau A; Bouchez S; Billaud E; Raffi F
J Antimicrob Chemother; 2014 Oct; 69(10):2804-8. PubMed ID: 24907142
[TBL] [Abstract][Full Text] [Related]
33. Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation.
Tosini W; Muller P; Prazuck T; Benabdelmoumen G; Peyrouse E; Christian B; Quertainmont Y; Bouvet E; Rabaud C
AIDS; 2010 Sep; 24(15):2375-80. PubMed ID: 20729709
[TBL] [Abstract][Full Text] [Related]
34. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers.
Blum MR; Chittick GE; Begley JA; Zong J
J Clin Pharmacol; 2007 Jun; 47(6):751-9. PubMed ID: 17519400
[TBL] [Abstract][Full Text] [Related]
35. FDA makes final approvals.
AIDS Patient Care STDS; 2006 May; 20(5):381. PubMed ID: 16758553
[No Abstract] [Full Text] [Related]
36. Lipid-lowering effect of tenofovir in HIV-infected patients.
Fabbiani M; Bracciale L; Doino M; Sidella L; Farina S; Di Cristo V; Cauda R; De Luca A; Di Giambenedetto S
J Antimicrob Chemother; 2011 Mar; 66(3):682-3. PubMed ID: 21131692
[No Abstract] [Full Text] [Related]
37. Minor emtricitabine intolerance in treatment-stable patients switched from tenofovir/lamivudine to a fixed-dose combination of tenofovir/emtricitabine (Truvada).
Palacios R; Terrón A; Hidalgo A; Rivero A; Santos J;
J Antimicrob Chemother; 2008 Feb; 61(2):462-3. PubMed ID: 18156608
[No Abstract] [Full Text] [Related]
38. Tenofovir/emtricitabine combination results in lower bone-mineral density.
AIDS Patient Care STDS; 2010 Apr; 24(4):265-6. PubMed ID: 20405529
[No Abstract] [Full Text] [Related]
39. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Mayer KH; Maslankowski LA; Gai F; El-Sadr WM; Justman J; Kwiecien A; Mâsse B; Eshleman SH; Hendrix C; Morrow K; Rooney JF; Soto-Torres L;
AIDS; 2006 Feb; 20(4):543-51. PubMed ID: 16470118
[TBL] [Abstract][Full Text] [Related]
40. Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
Hsu R; Lanier ER; Rouse EG; Oie KL; Pappa KA; Ross LL
Antivir Ther; 2008; 13(5):735-7. PubMed ID: 18771059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
